In the latest trading session, 13.12 million Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) shares changed hands as the company’s beta touched 0.68. With the company’s most recent per share price at $0.35 changing hands around $0.05 or 14.91% at last look, the market valuation stands at $2.08M. GLMD’s current price is a discount, trading about -157.14% off its 52-week high of $0.90. The share price had its 52-week low at $0.26, which suggests the last value was 25.71% up since then. When we look at Galmed Pharmaceuticals Ltd’s average trading volume, we note the 10-day average is 19000.0 shares, with the 3-month average coming to 48.32K.
Analysts gave the Galmed Pharmaceuticals Ltd (GLMD) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 7 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 3 recommended GLMD as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) trade information
Instantly GLMD is in green as seen in intraday trades today. With action 20.24%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -23.76%, with the 5-day performance at 20.24% in the green. However, in the 30-day time frame, Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) is 10.09% up. Looking at the short shares, we see there were 10246.0 shares sold at short interest cover period of 0.22 days.
Galmed Pharmaceuticals Ltd (GLMD) estimates and forecasts
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 21.08%.
GLMD Dividends
Galmed Pharmaceuticals Ltd is expected to release its next quarterly earnings report in September.
Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)’s Major holders
Among Mutual Funds, the top two as of Mar 31, 2024 were Delaware Group Equity Fds IV-Delaware Healthcare Fund and Fidelity NASDAQ Composite Index Fund. With 20.4 shares estimated at $7142.0 under it, the former controlled 0.08% of total outstanding shares. On the other hand, Fidelity NASDAQ Composite Index Fund held about 0.01% of the shares, roughly 1.81 shares worth around $634.0.
